Suppr超能文献

胆酸治疗胆汁酸合成缺陷的临床及生化有效性与安全性:一项系统评价

The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.

作者信息

Polak Yasmin, van Dussen Laura, Kemper E Marleen, Vaz Frédéric M, Klouwer Femke C C, Engelen Marc, Hollak Carla E M

机构信息

Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Medicines for Society, Platform at Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Orphanet J Rare Dis. 2024 Dec 19;19(1):466. doi: 10.1186/s13023-024-03449-7.

Abstract

BACKGROUND

Bile acid synthesis defects (BASDs) can be severely disabling involving the liver and nervous system, potentially due to elevated levels of toxic C-bile acid intermediates. Cholic acid (CA) supplementation is hypothesized to decrease bile acid production, stimulate bile secretion and -flow, and slowing down disease progression. This systematic review assesses the clinical and biochemical effectiveness, and safety of CA in BASDs patients.

METHODS

A systematic review of MEDLINE, Embase and clinical trial registries (ClinicalTrials.gov, ICTRP registry) using controlled MeSH- and Emtree terms.

RESULTS

From 526 articles 70 publications were deemed eligible for inclusion based on title and abstract. 14 publications were included after full-text assessment comprising case reports and -series with 1-35 patients (162 patients in total) receiving 1 week to 16,5 years of CA treatment. All presented data on effectiveness, 8 studies also presented data on safety. The included population concerned patients with Zellweger spectrum disorders (n = 73), 3β-Hydroxy-Δ5-C-steroid oxidoreductase deficiency (n = 62), cerebrotendinous xanthomatosis (n = 22), Δ4-3-oxosteroid 5β-reductase deficiency (n = 13), and α-methylacyl-CoA racemase deficiency (n = 3). Main outcomes concerned liver disease (12 studies), general physical examinations, biochemical outcomes, and safety (9 studies), and fat-soluble vitamin absorption (7 studies). The overall risk of bias score was considered to be critical (1 study), serious (4 studies), and moderate (9 studies). Major issues were missing data (10 studies), generalized data (8 studies), and no wash-out between treatments (4 studies).

CONCLUSION

More controlled studies are required as the available data is insufficient to draw definite conclusions on the effectiveness and safety of CA treatment in BASD patients. Establishing an independent international disease registry could better utilize existing real-world data.

摘要

背景

胆汁酸合成缺陷(BASDs)可严重致残,累及肝脏和神经系统,这可能是由于有毒的C胆汁酸中间体水平升高所致。据推测,补充胆酸(CA)可减少胆汁酸生成,刺激胆汁分泌和流动,并减缓疾病进展。本系统评价评估了CA对BASDs患者的临床和生化疗效及安全性。

方法

使用受控的医学主题词表(MeSH)和Emtree术语对MEDLINE、Embase和临床试验注册库(ClinicalTrials.gov、ICTRP注册库)进行系统评价。

结果

从526篇文章中,基于标题和摘要筛选出70篇符合纳入标准的文献。经过全文评估后,纳入了14篇文献,包括病例报告和病例系列,共162例患者,接受了1周至16.5年的CA治疗。所有文献均提供了疗效数据,8项研究还提供了安全性数据。纳入的患者群体包括泽尔韦格谱系障碍患者(n = 73)、3β-羟基-Δ5-C-类固醇氧化还原酶缺乏症患者(n = 62)、脑腱性黄瘤病患者(n = 22)、Δ4-3-氧代类固醇5β-还原酶缺乏症患者(n = 13)和α-甲基酰基辅酶A消旋酶缺乏症患者(n = 3)。主要结局包括肝脏疾病(12项研究)、一般体格检查、生化指标及安全性(9项研究)和脂溶性维生素吸收情况(7项研究)。偏倚风险总体评分被认为是关键(1项研究)、严重(4项研究)和中度(9项研究)。主要问题包括数据缺失(10项研究)、数据泛化(8项研究)以及治疗间无洗脱期(4项研究)。

结论

由于现有数据不足以就CA治疗BASD患者的有效性和安全性得出明确结论,因此需要更多对照研究。建立一个独立的国际疾病注册库可以更好地利用现有的真实世界数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验